Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 24.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 227,911 shares of the biotechnology company's stock after selling 73,962 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.36% of Blueprint Medicines worth $21,082,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Comerica Bank raised its position in Blueprint Medicines by 2,582.9% in the 1st quarter. Comerica Bank now owns 10,839 shares of the biotechnology company's stock worth $1,028,000 after purchasing an additional 10,435 shares during the period. CWM LLC lifted its stake in shares of Blueprint Medicines by 114.6% during the 2nd quarter. CWM LLC now owns 1,105 shares of the biotechnology company's stock worth $119,000 after acquiring an additional 590 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Blueprint Medicines by 82.8% during the 2nd quarter. SG Americas Securities LLC now owns 21,684 shares of the biotechnology company's stock worth $2,337,000 after acquiring an additional 9,819 shares during the last quarter. Diversified Trust Co boosted its holdings in Blueprint Medicines by 9.9% during the 2nd quarter. Diversified Trust Co now owns 15,910 shares of the biotechnology company's stock valued at $1,715,000 after acquiring an additional 1,438 shares during the period. Finally, Oak Ridge Investments LLC grew its position in Blueprint Medicines by 29.2% in the 2nd quarter. Oak Ridge Investments LLC now owns 15,744 shares of the biotechnology company's stock valued at $1,697,000 after acquiring an additional 3,555 shares during the last quarter.

Blueprint Medicines Price Performance

Shares of BPMC stock traded up $0.89 during trading hours on Friday, hitting $95.97. 373,649 shares of the company's stock were exchanged, compared to its average volume of 686,536. Blueprint Medicines Co. has a fifty-two week low of $71.97 and a fifty-two week high of $121.90. The firm has a market cap of $6.10 billion, a P/E ratio of -45.06 and a beta of 0.59. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The firm has a 50 day moving average of $91.55 and a two-hundred day moving average of $97.89.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, topping analysts' consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The company had revenue of $128.20 million during the quarter, compared to analysts' expectations of $127.56 million. During the same period in the prior year, the business posted ($2.20) earnings per share. The firm's revenue for the quarter was up 126.5% on a year-over-year basis. Sell-side analysts forecast that Blueprint Medicines Co. will post -3.68 EPS for the current year.

Analyst Ratings Changes

BPMC has been the subject of several research analyst reports. JMP Securities reiterated a "market outperform" rating and set a $125.00 target price on shares of Blueprint Medicines in a research report on Monday, November 18th. Needham & Company LLC reissued a "buy" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday, November 15th. Wells Fargo & Company decreased their target price on Blueprint Medicines from $153.00 to $151.00 and set an "overweight" rating for the company in a research report on Thursday, October 31st. HC Wainwright reaffirmed a "buy" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday, November 15th. Finally, StockNews.com upgraded Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $122.11.

Insider Activity at Blueprint Medicines

In other Blueprint Medicines news, insider Fouad Namouni sold 3,633 shares of the stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the sale, the insider now owns 69,070 shares in the company, valued at approximately $6,169,332.40. This represents a 5.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Christina Rossi sold 2,274 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $95.10, for a total value of $216,257.40. Following the transaction, the chief operating officer now owns 71,657 shares in the company, valued at approximately $6,814,580.70. This represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,260 shares of company stock valued at $768,057. 4.21% of the stock is owned by corporate insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.